Molecular Oncology Diagnostics Market to be dominated by Hospitals and Diagnostic Centers through 2028
Increased prevalence of
cancer and protein transformation in biomarker identification are expected to
drive the growth of Global Molecular Oncology Diagnostics Market during the
forecast period, 2024-2028.
According to
TechSci Research report, “Molecular
Oncology Diagnostics Market - Global Industry Size, Share, Trends, Competition,
Opportunity, and Forecast, 2018-2028,” the
Global
Molecular Oncology Diagnostics Market is expected to register an impressive
CAGR in the forecast period, 2023-2028 on account of rising prevalence of
cancer cases.
Cancer
is one of the most diagnosed diseases in the world. According to Global
Cancer Statistics 2021, around 1.9 million new instances of cancer were
expected to have been diagnosed.
However,
stringent regulatory scenario related to high cost of diagnostics procedures,
and side effects associated with imaging and the lack of awareness of early
diagnosis are likely to slow down the market growth in the coming years. Also, lack
of skilled professionals to conduct sensitive surgeries/biopsy pertaining to cancer
treatment especially in the emerging countries can further slowdown the market
growth.
Browse over XX
market data Figures spread through XX Pages and an in-depth TOC on "Molecular Oncology Diagnostics Market”
Global
Molecular Oncology Diagnostics Market can be segmented into product type, technology, application,
cancer type, end user, region and company. Based on product
type, the market
is segmented into instruments,
kits and assays, software. The segment kits
and assays is
expected to show an impressive growth in the forecast period due to its
simplicity in testing and integration in results.
Based
on technology, the market can be
segmented into fluorescence in-situ
hybridization (FISH), next-generation sequencing (NGS), polymerase chain reaction
(PCR), immunohistochemistry (IHC), and other technologies. As PCR targets NGS
sequencing and enables the concurrent generation of many NGS libraries and the
sequencing of numerous targeted regions, the segment polymerase chain reaction
(PCR) is expected to have remarkable growth in the future.
Based
on application, the market can be segmented
into research and clinical segments. Due to widespread adoption of technologies
like companion diagnostics and liquid biopsy, the clinical segment is
anticipated to experience excellent growth during the forecast period.
Based
on cancer type, the market is
segmented into solid tumors
and blood cancers. The
segment blood cancers are likely to show an
impressive growth in the forecast years due to rising prevalence of
hematological malignant cancers.
Based
on end user, the market is
segmented into hospitals and diagnostic
centers, reference laboratories, pharmaceutical and biotechnology companies, academic
and research institutes. The segment hospitals
and diagnostic centers is estimated to hold the largest share of the
market due to the high use of molecular oncology diagnostic tests by hospitals.
The leading companies operating in the Global
Molecular Oncology Diagnostics Market are:
- Sysmex Corporation
- F.
Hoffmann-La Roche Ltd.
- Myriad
Genetics, Inc.
- HTG
Molecular Diagnostics, Inc.
- Danaher
Corporation
- QIAGEN
N.V.
- Bio-Rad
Laboratories, Inc.
- Agilent
Technologies, Inc.
- QIAGEN
N.V.
- Illumina, Inc.
Download Free Sample Report
Customers can also request for 10% free
customization on this report.
“North
America is expected to dominate the Global Molecular Oncology Diagnostic Market
during the forecast period on account of rising patient awareness, new technology
development, and product launches. Additionally, high market penetration rate
of technologically advanced diagnostic products is expected to increase the
demand for Global Molecular Oncology Diagnostic Market in the coming years.”, said
Mr. Karan Chechi, Research Director with TechSci Research, a research based global
management consulting firm.
“Molecular Oncology Diagnostics Market -
Global Industry Size, Share, Trends, Competition, Opportunity, and Forecast,
2018-2028, Segmented By Product Type
(Instruments, Kits and Assays, Software), By Technology (Fluorescence In-Situ
Hybridization (FISH), Next-Generation Sequencing (NGS), Polymerase Chain
Reaction (PCR), Immunohistochemistry (IHC), Flow Cytometry, and Other
Technologies), By Application (Research, Clinical), By Cancer Type ({Solid
Tumor (Breast Cancer, Ovarian Cancer, Prostate Cancer, Lung Cancer, Colorectal
Cancer, and Other Solid Tumors), Blood Cancers (Lymphoma, Leukemia, Multiple
Myeloma, and other Hematological Malignancies)}, By End User (Hospitals and
Diagnostic Centers, Reference Laboratories, Pharmaceutical and Biotechnology
Companies, Academic and Research Institutes), By Region”, has evaluated the future growth potential of Global
Molecular Oncology Diagnostics Market and provides statistics & information
on market size, structure, and future market growth. The report intends to
provide cutting-edge market intelligence and help decision makers take sound
investment decisions. Besides, the report also identifies and analyzes the
emerging trends along with essential drivers, challenges, and opportunities in Global
Molecular Oncology Diagnostics Market.
Contact
Mr. Ken Mathews
708 Third Avenue,
Manhattan, NY,
New York – 10017
Tel: +1-646-360-1656
Email: [email protected]
Website: https://www.techsciresearch.com